The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boehringer Ingelheim; Novartis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Merck; Novartis
Temsirolimus-induced interstitial lung disease as an on-target effect in patients with metastatic renal cell carcinoma.
 
Masatoshi Eto
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Takeda
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst)
 
Takanobu Motoshima
No Relationships to Disclose
 
Yutaka Sugiyama
No Relationships to Disclose
 
Kiyohide Fujimoto
No Relationships to Disclose
 
Chikara Ohyama
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Astellas Pharma; Janssen; Pfizer
 
Koji Mita
No Relationships to Disclose
 
Naoya Masumori
Speakers' Bureau - Asahi Kasei; Astellas Pharma; AstraZeneca; Kissei Pharmaceutical; Nippon Shinyaku
Research Funding - Astellas Pharma (Inst); Takeda (Inst)
 
Toshiyuki Kamoto
No Relationships to Disclose
 
Koichiro Matsumoto
No Relationships to Disclose